首页 › 弥漫性大B细胞淋巴瘤 › 俄勒冈州 › Portland
Portland OR 弥漫性大B细胞淋巴瘤临床试验
15项针对 弥漫性大B细胞淋巴瘤的研究正在 Portland及周边约 30 英里内的站点招募参与者。打开研究详情可查看入选标准及联系研究团队的方式。
官方研究文本（英文）
正在为研究招募参与者？将此页面置顶展示 — $99 / 30天 →
Consolidation of First-Line MRD+ Remission With Cema-cel in Patients With LBCL
招募中2 期
- Oregon Health and Science University, Portland
Testing the Effectiveness of a Combination Targeted Therapy (ViPOR) for Patients With Relapsed and/or Refractory Aggressive B-cell Lymphoma
招募中2 期
- Providence Portland Medical Center, Portland
- Providence Saint Vincent Medical Center, Portland
A Study to Evaluate Zilovertamab Vedotin (MK-2140) Combination With Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Participants With Previously Untreated DLBCL (MK-2140-010)
招募中3 期
- Kaiser Permanente Interstate Medical Office - Central ( Site 0181), Portland
A Clinical Study of Zilovertamab Vedotin (MK-2140) Plus Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Polatuzumab Vedotin Plus R-CHP in People With Diffuse Large B-cell Lymphoma (DLBCL) (MK-2140-011/waveLINE-011)
招募中2 期
- Providence Portland Medical Center ( Site 0120), Portland
- Providence Oncology and Hematology Clinic Westside ( Site 0179), Portland
Vaccine Responses in Patient With Multiple Myeloma and Non-Hodgkin Lymphoma After CAR-T Treatment
招募中观察性研究
- OHSU Knight Cancer Institute, Portland
A Study of LY4584180 in Adult Participants With Previously Treated Blood Cancers
招募中1 期
- Oregon Health & Science University (OHSU), Portland
Substudy 01A: Zilovertamab Vedotin in Pediatric and Young Adult Participants With Hematologic Malignancies or Solid Tumors (MK-9999-01A/LIGHTBEAM-U01)
招募中1/2 期
- Oregon Health and Science University ( Site 1004), Portland
Evaluate Optimization of CRS Profile for Glofit Monotherapy and Glofit+GemOx in R/R Aggressive B-NHL
招募中2 期
- Providence Portland Medical Center, Portland
- Providence St. Vincent Medical Center, Portland
Gene Therapy for CD19-Positive Hematologic Malignancies (SENTRY-CD19)
招募中1/2 期
- Oregon Health & Science University, Portland
Lentiviral Gene Therapy (Zamtocabtagene Autoleucel) LTFU
招募中观察性研究
- Oregon Health and Science University Knight Cancer Institute, Portland
DALY II USA/ MB-CART2019.1 for DLBCL
招募中2 期
- Oregon Health and Science University Knight Cancer Institute, Portland
Mosunetuzumab With Chemotherapy for the Treatment of Patients With Untreated C-Myc Rearrangement Positive High Grade B Cell Lymphoma or Diffuse Large B Cell Lymphoma
招募中1/2 期
- OHSU Knight Cancer Institute, Portland
Testing Drug Treatments After CAR T-cell Therapy in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma
招募中2 期
- Providence Portland Medical Center, Portland
- Providence Saint Vincent Medical Center, Portland
- Oregon Health and Science University, Portland
- 以及另外 1 项
Study Adding Drugs to Usual Treatment for Large B-Cell Lymphoma That Returned or Did Not Respond to Treatment
招募中2 期
- Providence Portland Medical Center, Portland
- Providence Saint Vincent Medical Center, Portland
- Providence Willamette Falls Medical Center, Oregon City · 距离 12 英里
A Study of AC676 for the Treatment of Relapsed/Refractory B-Cell Malignancies
招募中1 期
- Oregon Health & Science University, Portland
其他城市的 弥漫性大B细胞淋巴瘤试验
- New York City, NY21 项研究
- Baldwin Park, CA19 项研究
- Chicago, IL18 项研究
- Houston, TX17 项研究
- Los Angeles, CA17 项研究
- Boston, MA16 项研究
- Milwaukee, WI16 项研究
- Nashville, TN15 项研究
- Philadelphia, PA15 项研究
- Durham, NC14 项研究
- Dallas, TX13 项研究
- Seattle, WA12 项研究
Portland的其他研究
- 非小细胞肺癌46 项研究
- 癌症（所有类型）34 项研究
- 前列腺癌33 项研究
- 乳腺癌33 项研究
- 转移性癌症29 项研究
- 结直肠癌28 项研究
- 卵巢癌27 项研究
- 肺癌26 项研究
- 急性髓系白血病25 项研究
- 子宫内膜癌24 项研究
- 头颈鳞状细胞癌19 项研究
- 胰腺癌19 项研究
数据来自 ClinicalTrials.gov，检索日期：2026年10月5日。每项研究自行设定入选标准，由研究团队决定谁能参与。